Clinical Trials on Hepatic Veno-Occlusive Disease

Total 11508 results

Mirati Therapeutics Inc.

Completed

A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib

Hepatic Impairment

United States
Corcept Therapeutics

Completed

A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant

Hepatic Impairment

United States
VectivBio AG

Completed

A Phase 1, Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function

Hepatic Impairment

Germany, Slovakia
Novartis Pharmaceuticals

Completed

Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.

Hepatic Impairment

United States
Insmed Incorporated

Completed

A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

Hepatic Impairment

United States
Cerevel Therapeutics, LLC

Completed

To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

Hepatic Impairment

United States
Shionogi

Completed

A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants

Hepatic Impairment

United States
Celgene

Completed

Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment

Hepatic Impairment

United States
AstraZeneca
Parexel

Terminated

Pharmacokinetics of Cotadutide in Participants With Hepatic Impairment

Hepatic Impairment

United States
Portola Pharmaceuticals

Completed

The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist

Hepatic Impairment

United States
AbbVie

Terminated

A Study to Assess Safety of Cedirogant and How Cedirogant Moves Through the Body in Adult Participants With Mild, Moderate and Severe Hepatic Impairment

Hepatic Impairment

United States
Zogenix, Inc.

Completed

Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Controlled-Release (HC-CR) in Subjects With Hepatic Impairment

Hepatic Impairment
Hutchison Medipharma Limited

Completed

Surufatinib Hepatic Impairment Study

Hepatic Impairment

United States
Kadmon, a Sanofi Company

Completed

KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment

Hepatic Impairment

United States
Galectin Therapeutics Inc.

Completed

A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment

Hepatic Impairment

United States
F2G Biotech GmbH

Completed

A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Bristol-Myers Squibb

Completed

A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver Impairment

Hepatic Impairment

United States
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Danicopan in Participants With Hepatic Impairment

Hepatic Impairment

United States
Janssen Research & Development, LLC

Terminated

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib

Hepatic Impairment

Germany
Daiichi Sankyo, Inc.

Completed

Study of Single-dose DS-3201b in Participants With Hepatic Impairment

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function

Hepatic Impairment

United States
Celgene

Completed

A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects

Hepatic Impairment

United States
Eisai Inc.

Completed

Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Pfizer

Completed

Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment

Hepatic Impairment

United States, Belgium, Czechia, Slovakia
Aragon Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function

Hepatic Impairment

United States
Ipsen

Completed

Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy Subjects

Hepatic Impairment

Moldova, Republic of, Romania
Eli Lilly and Company
AstraZeneca

Withdrawn

A Study of LY3314814 in Participants With Liver Impairment

Hepatic Impairment

United States
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Patients With Hepatic Impairment

Hepatic Impairment

China
Novartis Pharmaceuticals

Completed

A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers

Hepatic Impairment

Germany
Melinta Therapeutics, Inc.

Completed

Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment

Hepatic Impairment

United States
FORUM Pharmaceuticals Inc
PRA Health Sciences

Completed

EVP-6124 Hepatic Impairment Study

Hepatic Impairment

Czech Republic, Poland, Slovakia
LG Life Sciences

Completed

Influence of Hepatic Impairment on Pharmacokinetic (PK) and Pharmacodynamic (PD) of Gemigliptin PK and PD After Multiple Oral Doses in Healthy White Volunteers

Hepatic Impairment

Germany
Janssen Research & Development, LLC

Completed

A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients With Normal Hepatic Function

Hepatic Impairment

United States
Sanofi

Completed

Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild and Moderate Hepatic Impairment

Hepatic Impairment

United States
Sanofi

Completed

Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Newron Pharmaceuticals SPA

Completed

A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics

Hepatic Impairment

Germany
Cephalon

Completed

A Study to Evaluate the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Hepatic Function and Subjects With Moderate Hepatic Impairment

Hepatic Impairment

United States
Biogen

Completed

BG9928 in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Johann Wolfgang Goethe University Hospital

Completed

Evaluation of Patients With Vena Cava Inferior Thrombosis

Venous Thromboembolism | Inferior Vena Cava Thrombosis

Germany
National Institute of Diabetes and Digestive and...
Ann & Robert H Lurie Children's Hospital of Chicago

Recruiting

TReatment for ImmUne Mediated PathopHysiology (TRIUMPH)

Hepatic Encephalopathy | Acute Liver Failure | Fulminant Hepatic Failure | Acute Liver Injury | Immune Dysregulation

United States
Unity Health Toronto
Applied Health Research Centre

Recruiting

Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery (NEWTON-CABG)

Atherosclerosis | Coronary Artery Bypass Graft Surgery | Vein Occlusion

Canada, United States
AstraZeneca

Recruiting

A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693

Hepatic Impairment

United States
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject

Hepatic Impairment

China
CTI BioPharma
PPD

Recruiting

Study to Evaluate the Safety, Tolerability, and PK of Pacritinib

Hepatic Impairment

United States
Chipscreen Biosciences, Ltd.

Recruiting

Pharmacokinetics of Chiglitazar in Subjects With Hepatic Impairment and Normal Hepatic Function

Hepatic Impairment

China
Eisai Co., Ltd.

Recruiting

Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants

Hepatic Impairment

Japan
SK Life Science, Inc.

Completed

Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment

Hepatic Impairment

Poland, Slovakia
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

Hepatic Impairment
Novartis Pharmaceuticals

Completed

A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy Participants

Hepatic Impairment

Hungary
Institut de Recherches Internationales Servier

Completed

A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic Function

Hepatic Impairment

United States

3

Subscribe